Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBIT (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of EBIT data on record, last reported at $18.4 million in Q4 2025.

  • For Q4 2025, EBIT rose 340.92% year-over-year to $18.4 million; the TTM value through Dec 2025 reached -$12.2 million, up 90.48%, while the annual FY2025 figure was -$12.2 million, 90.48% up from the prior year.
  • EBIT reached $18.4 million in Q4 2025 per ARQT's latest filing, up from $8.5 million in the prior quarter.
  • Across five years, EBIT topped out at $18.4 million in Q4 2025 and bottomed at -$104.7 million in Q3 2022.
  • Average EBIT over 5 years is -$44.5 million, with a median of -$46.1 million recorded in 2021.
  • Peak YoY movement for EBIT: crashed 109.27% in 2021, then soared 340.92% in 2025.
  • A 5-year view of EBIT shows it stood at -$71.3 million in 2021, then rose by 4.01% to -$68.4 million in 2022, then rose by 10.6% to -$61.2 million in 2023, then soared by 87.52% to -$7.6 million in 2024, then skyrocketed by 340.92% to $18.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $18.4 million in Q4 2025, $8.5 million in Q3 2025, and -$14.6 million in Q2 2025.